What is the regulatory and approval status of ARA-290?

ARA-290, also known as cibinetide, has never been approved for marketing by any national regulatory authority, and its entire regulatory footprint is investigational. The compound reached small Phase 2 trials under investigational new drug provisions and stalled there, which leaves orphan drug designation as the single most misread fact about it, since designation is an early incentive status rather than a finding on safety, efficacy, or permission to sell. Nothing in the record supports any of the alternative legal categories that unapproved compounds are sometimes marketed under.

Has ARA-290 been approved for marketing by the FDA, the EMA, or any other national regulator?

Marketing approval is a recorded act with a public paper trail, not an impression a reader forms from clinical vocabulary. Every register that would carry an ARA-290 authorisation is free, searchable, and continuously updated, so the question resolves in minutes rather than on trust. That gap between verifiable fact and inferred legitimacy is where most sellers operate, because vendor sites rarely state approval outright; they surround the compound with genuine peer-reviewed studies and designation status and let the reader supply the conclusion.

• United States registers: No New Drug Application in Drugs@FDA, no Orange Book listing with patent or exclusivity data.
• European Union: No centralised marketing authorisation, and no national authorisation through the decentralised or mutual recognition routes.
• Other major systems: Absent from the Canadian, United Kingdom, Australian, and Japanese public product registers.
• Unapproved, not refused: Never rejected; development stopped before an application could be filed.

What does orphan drug designation actually grant, and why is it not the same as approval?

Designation is an incentive, not a verdict, and the distance between the two is where a great deal of misleading marketing lives. A sponsor can obtain it on preclinical data, mechanistic argument, and early safety observations alone, with no requirement to have shown benefit in a controlled trial. A seller who writes that a compound holds orphan drug designation from the FDA says something literally true while the reader hears agency endorsement.

How far did ARA-290 progress through registered clinical trials, and what is its current development status?

Development reached Phase 2 and stopped there. The registered human work was small by pharmaceutical standards, enrolling on the order of tens of participants over weeks of daily subcutaneous dosing and powered to detect signals rather than to establish clinical benefit. The most informative fact about current status is elapsed time: a program whose newest registered study is many years old, with no successor trial and no filing, has stalled.

Is ARA-290 permitted as a compounded preparation under FDA bulk drug substance rules?

Compounding gets described as a legal side door for unapproved compounds, and for this one the door is closed. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act exempt qualifying preparations from new drug approval, but only inside tightly drawn boundaries that ARA-290 does not enter. For a pharmacy the consequence is concrete rather than theoretical, because an ineligible bulk substance turns every preparation made from it into an unapproved new drug.

• The 503A eligibility test: A compendial monograph, a component of an approved drug, or placement on the agency list.
• ARA-290 against that test: Meets none of the three, and appears on neither the 503A nor the 503B list.
• Injectable peptides as a class: Flagged for immunogenicity from aggregation, peptide-related impurities, and absent safety data by route.
• Pharmacy exposure: Warning letters, seizure, injunction, state board discipline, and loss of the 503A exemption.

What does a research use only label mean in law, and what does it not authorize?

Research use only is a disclaimer, not a status. The phrase originates in labelling rules for in vitro diagnostic products and was borrowed by chemical and peptide suppliers for substances with no approval and no lawful clinical use. It is also weaker protection than sellers assume, because intended use is determined by the totality of circumstances rather than by the sticker on the vial.

Can ARA-290 be legally sold as a dietary supplement or nutraceutical ingredient?

Two independent barriers block this route, and either one alone would be decisive. A synthetic 11 amino acid peptide engineered to bind a specific receptor is not an amino acid in the statutory sense any more than insulin is, and an injectable product is not intended for ingestion. The practical harm of the supplement framing is that the word signals low stakes and casual use, which is the wrong mental model for an unapproved injectable investigational drug.

• Statutory definition: A synthetic receptor-binding peptide is not a dietary ingredient under the definition.
• Route of administration: Injectable products fail the intended-for-ingestion threshold before any further analysis.
• Drug preclusion clause: Prior authorised investigation as a new drug permanently forecloses supplement status.
• Enforcement record: Warning letters and injunction actions have targeted firms selling injectable peptides under supplement labelling.

What legal exposure exists for suppliers and buyers of unapproved peptides sold online?

The exposure is asymmetric, falling most heavily on sellers and prescribers rather than on individual buyers. Introducing an unapproved new drug into interstate commerce violates the Federal Food, Drug, and Cosmetic Act directly, and the same product is usually misbranded as well for lacking adequate directions for use. The rarity of prosecution against individual purchasers gets misread as permission, when the real cost to the buyer is clinical and financial rather than legal.

What would a sponsor need to complete before ARA-290 could reach approval?

The pathway determines everything downstream, and for this compound it is settled by size. What usually stops a program at exactly this stage is capital rather than science, since a Phase 3 neuropathy program is a large multi-year commitment that a small sponsor cannot fund alone. Approval would change the picture completely: a defined indication, an approved label with dosing and contraindications, pharmacovigilance, manufacturing oversight, and a legitimate prescribing route in place of a grey market.

1. Pathway determination: At 11 amino acids the compound falls below the 40 amino acid threshold separating biologics from drugs, so review proceeds under a New Drug Application.
2. End of Phase 2 meeting: The sponsor agrees a development plan with the agency before committing to pivotal work.
3. Pivotal trials: At least one and usually two adequate and well controlled trials in a defined population, randomised against placebo, powered on a clinically meaningful primary endpoint, with a prespecified analysis plan and months rather than weeks of exposure.
4. Chemistry, manufacturing, and controls package: Validated synthesis, defined impurity limits, sterility and endotoxin control for an injectable, container closure and stability data, and commercial scale process validation.
5. Filing and review: Submission of the application, with the existing orphan designation waiving the user fee and expedited routes such as fast track or priority review potentially available.

How do import rules and customs enforcement treat unapproved investigational peptides?

At the border the analysis is mechanical, and the burden runs against the importer rather than the agency. Investigational peptides bought from overseas suppliers meet the description of an unapproved or misbranded new drug on their face, which is enough for refusal without any showing of harm. Declaring the parcel as something else converts a customs refusal into a potential false declaration.

1. Presumption at entry: An article that appears to be an unapproved new drug or misbranded may be refused admission, with the importer bearing the burden of showing admissibility.
2. Import alerts: Where a pattern of violation exists, named products, shippers, or countries of origin are subject to detention without physical examination, which is why entire categories of peptide shipments are held routinely.
3. Detention notice: A window to respond follows, and admissibility must be established on the record.
4. Refusal: Product that cannot be shown admissible is exported or destroyed, usually at the importer's expense.

How is ARA-290 treated under sport anti-doping rules?

For an athlete under the World Anti-Doping Code the answer does not turn on pharmacology at all. The prohibited list opens with a category covering non-approved substances, and ARA-290 sits inside that definition precisely because no regulator anywhere has authorised it for human therapeutic use. Whether it also falls under the peptide hormones section is arguable given its non-hematopoietic design, and academic, since the code does not require a substance to appear on the list by name.

• Non-approved substances category: Covers any pharmacological substance without current human therapeutic approval from any regulator.
• Prohibited status: In competition and out of competition alike, at all times.
• Therapeutic use exemption: Unavailable, since exemptions apply only to approved medicines for a diagnosed condition.
• Consequences of an adverse finding: Provisional suspension through multi-year ineligibility and disqualification of results, largely independent of intent.